Welcome to our dedicated page for Foghorn Therapeutics SEC filings (Ticker: FHTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
R&D burn rates, clinical milestones and intricate chromatin biology risks fill every Foghorn Therapeutics (FHTX) disclosure. Finding the exact trial update or gauging cash runway in a 10-K can feel like decoding epigenetic jargon. If you have ever searched “Foghorn Therapeutics SEC filings explained simply,” you already know the challenge.
Stock Titan turns that complexity into clarity. Our AI reads each document the instant it hits EDGAR, then delivers concise summaries, plain-English definitions and red-flag alerts. Need the latest Foghorn Therapeutics quarterly earnings report 10-Q filing or want to understand the 8-K announcing a new SMARCA2 study cohort? It’s here, parsed and linked to key metrics. Forms covered include:
- 10-K: annual report with AI-highlighted R&D expense trends and Gene Traffic Control platform updates
- 10-Q: quarter-to-quarter pipeline progress and liquidity analysis
- 8-K: material events—trial pauses, collaboration amendments—explained line by line
- Form 4: Foghorn Therapeutics insider trading Form 4 transactions streamed in real time, plus trend charts
- DEF 14A: proxy statement executive compensation breakdown
Professionals use these insights to monitor segment spending, compare enrollment timelines and track Foghorn Therapeutics executive stock transactions Form 4 before catalyst events. Whether you are preparing a valuation model or just want Foghorn Therapeutics annual report 10-K simplified, our platform answers natural language questions such as “What does FHTX report about BRD9 degrader trials?” or “Where can I find FHTX insider Form 4 filings in real time?”—all without sifting through hundreds of pages.
Foghorn Therapeutics (FHTX) Q2-25 10-Q highlights:
- Revenue: Collaboration income with Eli Lilly rose 10% YoY to $7.6 m; H1-25 revenue up 13% to $13.5 m.
- Expenses: R&D fell 8% to $21.8 m and G&A fell 6% to $6.9 m, driving a 15% narrower operating loss of $21.1 m.
- Net loss: Q2 loss improved to $17.9 m (-$0.28/sh) from $23.0 m (-$0.45/sh) last year; H1 loss narrowed to $36.8 m (-$0.58/sh).
- Liquidity: Cash & cash equivalents $72.6 m; marketable securities $126.1 m; combined liquid resources $198.7 m. Management expects runway ≥12 months despite $45 m operating cash burn in H1.
- Balance sheet: Deferred revenue declined to $266.6 m as collaboration work progresses; total liabilities $302.9 m exceed assets $226.2 m, producing a $76.7 m shareholders’ deficit.
- Operations: FHD-909 (SMARCA2) transitioned to Lilly with 50/50 cost share; FHD-286 development discontinued (2024). New 10-year Watertown lease signed; Cambridge lease partially reduced, lowering future obligations by $8.5 m.
Key takeaways: Expense discipline and steady milestone revenue trimmed losses, but the pre-commercial company remains cash-burning and carries a negative equity position. Progress of the Lilly collaboration and access to additional capital remain critical catalysts.
FAQ
What is the current stock price of Foghorn Therapeutics (FHTX)?
What is the market cap of Foghorn Therapeutics (FHTX)?
